IDEXX Laboratories (IDXX)
(Real Time Quote from BATS)
$361.24 USD
+12.03 (3.45%)
Updated Jun 29, 2022 02:14 PM ET
4-Sell of 5 4
C Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for IDEXX Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 | |
---|---|---|---|---|---|
Sales | 3,215 | 2,707 | 2,407 | 2,213 | 1,969 |
Cost Of Goods | 1,326 | 1,136 | 1,041 | 972 | 872 |
Gross Profit | 1,889 | 1,571 | 1,366 | 1,242 | 1,097 |
Selling & Adminstrative & Depr. & Amort Expenses | 957 | 877 | 813 | 750 | 684 |
Income After Depreciation & Amortization | 932 | 695 | 553 | 491 | 413 |
Non-Operating Income | 0 | 1 | 0 | 1 | 5 |
Interest Expense | 30 | 33 | 31 | 35 | 37 |
Pretax Income | 903 | 662 | 522 | 458 | 381 |
Income Taxes | 158 | 80 | 94 | 81 | 118 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 745 | 582 | 428 | 377 | 263 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income | 745 | 582 | 428 | 377 | 263 |
Depreciation Footnote | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,037 | 791 | 641 | 575 | 496 |
Depreciation & Amortization (Cash Flow) | 105 | 96 | 88 | 83 | 83 |
Income After Depreciation & Amortization | 932 | 695 | 553 | 491 | 413 |
Earnings Per Share Data | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Average Shares | 86.57 | 86.72 | 87.54 | 88.47 | 89.57 |
Diluted EPS Before Non-Recurring Items | 8.60 | 6.71 | 4.89 | 4.26 | 3.28 |
Diluted Net EPS | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 |
Fiscal Year end for IDEXX Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 | |
---|---|---|---|---|---|
Sales | 836.55 | 801.09 | 810.42 | 826.14 | 777.71 |
Cost Of Goods | 337.80 | 344.67 | 337.50 | 336.83 | 306.93 |
Gross Profit | 498.75 | 456.42 | 472.92 | 489.31 | 470.78 |
SG&A, R&D, and Dept/Amort Expenses | 250.41 | 257.23 | 246.96 | 230.06 | 223.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 248.34 | 199.19 | 225.96 | 259.25 | 247.62 |
Non-Operating Income | 0.14 | 0.17 | 0.12 | 0.09 | 0.05 |
Interest Expense | 7.00 | 7.48 | 7.13 | 7.61 | 7.58 |
Pretax Income | 241.49 | 191.88 | 218.95 | 251.73 | 240.09 |
Income Taxes | 47.53 | 29.11 | 43.77 | 49.13 | 35.80 |
Minority Interest | 0.00 | 0.00 | -0.06 | 0.02 | 0.03 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 193.97 | 162.77 | 175.18 | 202.61 | 204.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | 193.97 | 162.77 | 175.24 | 202.58 | 204.26 |
Earnings Per Share Data | 3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 |
---|---|---|---|---|---|
Average Shares | 85.56 | 86.14 | 86.51 | 86.65 | 86.92 |
Diluted EPS Before Non-Recurring Items | 2.27 | 1.89 | 2.03 | 2.34 | 2.35 |
Diluted Net EPS | 2.27 | 1.88 | 2.03 | 2.34 | 2.35 |